crinetics.png
Crinetics Pharmaceuticals Showcasing Breadth of Pipeline at ENDO 2021 with Presentations on Three Clinical Programs
March 12, 2021 07:10 ET | Crinetics Pharmaceuticals, Inc.
- Details of New Paltusotine Tablet Formulation to be Unveiled - - Preclinical Evidence Supporting Programs in Congenital Hyperinsulinism and Congenital Adrenal Hyperplasia and Cushing’s Disease...
Eckert & Ziegler’s GalliaPharm® distributed by Curium in France
March 01, 2021 19:15 ET | Curium
Berlin, Germany and Paris, France, March 01, 2021 (GLOBE NEWSWIRE) -- Eckert & Ziegler Radiopharma GmbH and Curium PET France have decided to reinforce their existing long term partnership by...
RadioMedix wins 2020 TechConnect Innovation Award and pitched at Virtual TechConnect Business Summit
January 04, 2021 11:00 ET | RadioMedix Inc.
Houston (TX), Jan. 04, 2021 (GLOBE NEWSWIRE) -- RadioMedix Inc. Houston-based clinical-stage radiopharmaceutical company is proud to announce that the company was selected for...
crinetics.png
Crinetics Pharmaceuticals Reports Second Quarter 2020 Financial Results and Provides Corporate Update
August 07, 2020 07:30 ET | Crinetics Pharmaceuticals, Inc.
Paltusotine received Orphan Drug Designation for the treatment of acromegaly Half of the enrolled patients in the ongoing Phase 2 ACROBAT Edge clinical trial for paltusotine had completed the study...
crinetics.png
Crinetics Pharmaceuticals Receives Orphan Drug Designation for Paltusotine for the Treatment of Acromegaly
July 08, 2020 16:05 ET | Crinetics Pharmaceuticals, Inc.
SAN DIEGO, July 08, 2020 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of...
crinetics.png
Crinetics Pharmaceuticals Confirms Completion for Half of the Enrolled Patients in the Ongoing Phase 2 ACROBAT Edge Clinical Trial for Paltusotine
June 11, 2020 07:30 ET | Crinetics Pharmaceuticals, Inc.
28 patients have completed the open-label Edge trial measuring IGF-1 levels after 13 weeks of treatment when patients with acromegaly were switched to once daily oral paltusotine from commercially...
crinetics.png
Crinetics Pharmaceuticals Appoints Adriana Cabré, MBA, as Vice President of Human Resources
May 27, 2020 07:30 ET | Crinetics Pharmaceuticals, Inc.
SAN DIEGO, May 27, 2020 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of...
crinetics.png
Crinetics Pharmaceuticals Reports First Quarter 2020 Financial Results and Provides Corporate Update
May 08, 2020 09:01 ET | Crinetics Pharmaceuticals, Inc.
Reported positive interim results for the ACROBAT Edge Phase 2 trial of oral paltusotine in the treatment of acromegaly Completed successful public offering raising net proceeds of $107.9 million ...
crinetics.png
Crinetics Pharmaceuticals Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
April 17, 2020 16:05 ET | Crinetics Pharmaceuticals, Inc.
SAN DIEGO, April 17, 2020 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of...
crinetics.png
Crinetics Pharmaceuticals Announces Pricing of Public Offering of Common Stock
April 15, 2020 00:21 ET | Crinetics Pharmaceuticals, Inc.
SAN DIEGO, April 15, 2020 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of...